View Item 

Show simple item record

Structure–activity Relationships of Amyloid Beta-aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility
dc.contributor.authorReinke, Ashley A.en_US
dc.contributor.authorGestwicki, Jason E.en_US
dc.date.accessioned2010-04-01T15:48:00Z
dc.date.available2010-04-01T15:48:00Z
dc.date.issued2007-09en_US
dc.identifier.citationReinke, Ashley A.; Gestwicki, Jason E. (2007). "Structure–activity Relationships of Amyloid Beta-aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility." Chemical Biology & Drug Design 70(3): 206-215. <http://hdl.handle.net/2027.42/66293>en_US
dc.identifier.issn1747-0277en_US
dc.identifier.issn1747-0285en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/66293
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17718715&dopt=citationen_US
dc.format.extent593851 bytes
dc.format.extent3110 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 The Authors Journal compilation 2007 Blackwell Munksgaarden_US
dc.subject.otherAlzheimer's Diseaseen_US
dc.subject.otherNeurodegenerationen_US
dc.subject.otherProtein Misfoldingen_US
dc.subject.otherThioflavin Ten_US
dc.titleStructure–activity Relationships of Amyloid Beta-aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibilityen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid17718715en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/66293/1/j.1747-0285.2007.00557.x.pdf
dc.identifier.doi10.1111/j.1747-0285.2007.00557.xen_US
dc.identifier.sourceChemical Biology & Drug Designen_US
dc.identifier.citedreferenceSelkoe D.J. ( 1991 ) The molecular pathology of Alzheimer’s disease. Neuron ; 6 : 487 – 498.en_US
dc.identifier.citedreferenceCaughey B., Lansbury P.T. ( 2003 ) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Ann Rev Neurosci ; 26 : 267 – 298.en_US
dc.identifier.citedreferenceGlabe C.C. ( 2005 ) Amyloid accumulation and pathogensis of Alzheimer’s disease: significance of monomeric, oligomeric and fibrillar Abeta. Biochemistry ; 38 : 167 – 177.en_US
dc.identifier.citedreferenceJarrett J.T., Lansbury P.T. Jr ( 1993 ) Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell ; 73 : 1055 – 1058.en_US
dc.identifier.citedreferenceMorgan C., Colombres M., Nunez M.T., Inestrosa N.C. ( 2004 ) Structure and function of amyloid in Alzheimer’s disease. Progress Neurobiol ; 74 : 323 – 349.en_US
dc.identifier.citedreferenceSmith T.J., Stains C.I., Meyer S.C., Ghosh I. ( 2005 ) Inhibition of beta-amyloid fibrillization by directed evolution of a beta-sheet presenting miniature protein. J Am Chem Soc ; 128 : 14456 – 14457.en_US
dc.identifier.citedreferenceUrbanc B., Cruz L., Teplow D.B., Stanley H.E. ( 2006 ) Computer simulations of Alzheimer’s amyloid beta-protein folding and assembly. Current Alzheimers Res ; 3 : 493 – 504.en_US
dc.identifier.citedreferenceHaass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L. et al. ( 1992 ) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature ; 359 : 322 – 325.en_US
dc.identifier.citedreferenceGhosh A.K., Kumaragurubaran N., Tang J. ( 2005 ) Recent developments of structure based beta-secretase inhibitors for Alzheimer’s disease. Curr Topics Med Chem ; 5 : 1609 – 1622.en_US
dc.identifier.citedreferenceGlabe C.G., Kayed R. ( 2006 ) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology ; 66 : S74 – S78.en_US
dc.identifier.citedreferenceWalsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., Selkoe D.J. ( 2002 ) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans ; 30 : 552 – 557.en_US
dc.identifier.citedreferenceBarghorn S., Nimmrich V., Striebinger A., Krantz C., Keller P., Janson B. et al. ( 2005 ) Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem ; 95 : 834 – 847.en_US
dc.identifier.citedreferenceFindeis M.A. ( 2000 ) Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochem Biophys Acta ; 1502 : 76 – 84.en_US
dc.identifier.citedreferenceLee V.M. ( 2002 ) Amyloid binding ligands as Alzheimer’s disease therapies. Neurobiol Aging ; 23 : 1039 – 1042.en_US
dc.identifier.citedreferenceCohen F.E., Kelly J.W. ( 2003 ) Therapeutic approaches to protein-misfolding diseases. Nature ; 426 : 905 – 909.en_US
dc.identifier.citedreferenceEvans C.G., Wisen S., Gestwicki J.E. ( 2006 ) Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem ; 281 : 33182 – 33191.en_US
dc.identifier.citedreferenceMakin O.S., Serpell L.C. ( 2005 ) Structures for amyloid fibrils. FEBS J ; 272 : 5950 – 5961.en_US
dc.identifier.citedreferenceLuhrs T., Ritter C., Adrian M., Riek-Loher D., Bohrmann B., Dobeli H., et al. ( 2005 ) 3D structure of Alzheimer’s amyloid-beta (1-42) fibrils. Proc Natl Acad Sci USA ; 102 : 17342 – 17347.en_US
dc.identifier.citedreferenceMakabe K., McElheny D., Tereshko V., Hilyard A., Gawlak G., Yan S., et al. ( 2006 ) Atomic structures of peptide self-assembly mimics. Proc Natl Acad Sci USA ; 103 : 17753 – 17758.en_US
dc.identifier.citedreferenceBuchete N.V., Hummer G. ( 2007 ) Structure and dynamics of parallel beta-sheets, hydrophobic core, and loops in Alzheimer’s A beta fibrils. Biophys J ; 92 : 3032 – 3039.en_US
dc.identifier.citedreferenceEisenberg D., Nelson R., Sawaya M.R., Balbirnie M., Sambashivan S., Ivanova M.I. et al. ( 2006 ) The structural biology of protein aggregation diseases: Fundamental questions and some answers. Acc Chem Res ; 39 : 568 – 575.en_US
dc.identifier.citedreferenceOyler N.A., Tycko R. ( 2004 ) Absolute structural constraints on amyloid fibrils from solid-state NMR spectroscopy of partially oriented samples. J Am Chem Soc ; 126 : 4478 – 4479.en_US
dc.identifier.citedreferenceKlunk W.E., Pettegrew J.W., Abraham D.J. ( 1989 ) Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem ; 37 : 1273 – 1281.en_US
dc.identifier.citedreferenceLorenzo A., Yankner B.A. ( 1994 ) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA ; 91 : 12243 – 12247.en_US
dc.identifier.citedreferenceKlunk W.E., Debnath M.L., Pettegrew J.W. ( 1995 ) Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiology of aging ; 16 : 541 – 548.en_US
dc.identifier.citedreferenceYang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S. et al. ( 2005 ) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem ; 280 : 5892 – 5901.en_US
dc.identifier.citedreferenceRyu E.K., Choe Y.S., Lee K.H., Choi Y., Kim B.T. ( 2006 ) Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem ; 49 : 6111 – 6119.en_US
dc.identifier.citedreferenceOno K., Hasegawa K., Naiki H., Yamada M. ( 2004 ) Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res ; 75 : 742 – 750.en_US
dc.identifier.citedreferenceNecula M., Kayed R., Milton S., Glabe C.G. ( 2007 ) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem ; 2007 Apr ; 282 : 10311 – 10324.en_US
dc.identifier.citedreferenceKung H.F., Lee C.W., Zhuang Z.P., Kung M.P., Hou C., Plossl K. ( 2001 ) Novel stilbenes as probes for amyloid plaques. J Am Chem Soc ; 123 : 12740 – 12471.en_US
dc.identifier.citedreferenceRiviere C., Richard T., Quentin L., Krisa S., Merillon J.M., Monti J.P. ( 2007 ) Inhibitory activity of stilbenes on Alzheimer’s beta-amyloid fibrils in vitro. Bioorganic & medicinal chemistry ; 15 : 1160 – 1167.en_US
dc.identifier.citedreferenceLee K.H., Shin B.H., Shin K.J., Kim D.J., Yu J. ( 2005 ) A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42). Biochem Biophys Res Commun ; 328 : 816 – 823.en_US
dc.identifier.citedreferencePorat Y., Abramowitz A., Gazit E. ( 2006 ) Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Design ; 67 : 27 – 37.en_US
dc.identifier.citedreferenceTaniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M. et al. ( 2005 ) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem ; 280 : 7614 – 7623.en_US
dc.identifier.citedreferenceMasuda M., Suzuki N., Taniguchi S., Oikawa T., Nonaka T., Iwatsubo T. et al. ( 2006 ) Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry ; 45 : 6085 – 6094.en_US
dc.identifier.citedreferenceNaiki H., Hasegawa K., Yamaguchi I., Nakamura H., Gejyo F., Nakakuki K. ( 1998 ) Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer’s beta-amyloid fibril formation in vitro. Biochemistry ; 37 : 1782 – 1789.en_US
dc.identifier.citedreferenceMoss M.A., Varvel N.H., Nichols M.R., Reed D.K., Rosenberry T.L. ( 2004 ) Nordihydroguaiaretic acid does not disaggregate beta-amyloid (1-40) protofibrils but does inhibit growth arising from direct protofibril association. Mol Pharm ; 66 : 592 – 600.en_US
dc.identifier.citedreferenceNakagami Y., Nishimura S., Murasugi T., Kaneko I., Meguro M., Marumoto S. et al. ( 2002 ) A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. British J Pharmacol ; 137 : 676 – 682.en_US
dc.identifier.citedreferenceYe L., Morgenstern J.L., Gee A.D., Hong G., Brown J., Lockhart A. ( 2005 ) Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem ; 280 : 23599 – 23604.en_US
dc.identifier.citedreferenceAnsari F.L., Nazir S., Noureen H., Mirza B. ( 2005 ) Combinatorial synthesis and antibacterial evaluation of an indexed chalcone library. Chem Biodiversity ; 2 : 1656 – 1664.en_US
dc.identifier.citedreferenceSpasova M., Kortenska-Kancheva V., Totseva I., Ivanova G., Georgiev L., Milkova T. ( 2006 ) Synthesis of cinnamoyl and hydroxycinnamoyl amino acid conjugates and evaluation of their antioxidant activity. J Pept Sci ; 12 : 369 – 375.en_US
dc.identifier.citedreferencePlater M.J., Jackson T. ( 2003 ) Polyaromatic amines. Part 3: Synthesis of poly(diarylamino)styrenes and related compounds. Tetrahedron ; 59 : 4673 – 4685.en_US
dc.identifier.citedreferenceHodgman C.D., Veazey W.R., Weast R.C. Chemical Rubber Company. ( 1998 ) Handbook of chemistry and physics; a ready-reference book of chemical and physical data. Cleveland : Cleveland Rubber Co.en_US
dc.identifier.citedreferenceOrtica F., Rodgers M.A. ( 2001 ) A laser flash photolysis study of curcumin in dioxane-water mixtures. Photochem Photobiol ; 74 : 745 – 751.en_US
dc.identifier.citedreferenceLeVine H. III ( 1993 ) Thioflavin T interaction with synthetic Alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Prot Sci ; 2 : 404 – 410.en_US
dc.identifier.citedreferenceLeVine H. III ( 1999 ) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol ; 309 : 274 – 284.en_US
dc.identifier.citedreferenceDe Felice F.G., Vieira M.N., Saraiva L.M., Figueroa-Villar J.D., Garcia-Abreu J., Liu R. et al. ( 2004 ) Targeting the neurotoxic species in Alzheimer’s disease: inhibitors of Abeta oligomerization. Faseb J ; 18 : 1366 – 1372.en_US
dc.identifier.citedreferenceShivaprasad S., Wetzel R. ( 2006 ) Scanning cysteine mutagenesis analysis of Abeta-(1-40) amyloid fibrils. J Biol Chem ; 281 : 993 – 1000.en_US
dc.identifier.citedreferenceWilliams A.D., Shivaprasad S., Wetzel R. ( 2006 ) Alanine scanning mutagenesis of Abeta-(1-40) amyloid fibril stability. J Mol Biol ; 357 : 1283 – 1294.en_US
dc.identifier.citedreferenceCampiglia P., Esposito C., Scrima M., Gomez-Monterrey I., Bertamino A., Grieco P. et al. ( 2007 ) Conformational stability of Abeta-(25-35) in the presence of thiazolidine derivatives. Chem Biol Drug Design ; 69 : 111 – 118.en_US
dc.identifier.citedreferenceZhuang Z.P., Kung M.P., Wilson A., Lee C.W., Plossl K., Hou C. et al. ( 2003 ) Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. J Med Chem ; 46 : 237 – 243.en_US
dc.identifier.citedreferenceChandra R., Kung M.P., Kung H.F. ( 2006 ) Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett ; 16 : 1350 – 1352.en_US
dc.identifier.citedreferenceLockhart A., Ye L., Judd D.B., Merritt A.T., Lowe P.N., Morgenstern J.L. et al. ( 2005 ) Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer’s disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem ; 280 : 7677 – 7684.en_US
dc.identifier.citedreferenceLeVine H. 3rd ( 2005 ) Mechanism of Abeta(1-40) fibril-induced fluorescence of (trans,trans)-1-bromo-2,5-bis(4-hydroxystyryl)benzene (K114). Biochemistry ; 44 : 15937 – 15943.en_US
dc.identifier.citedreferenceNesterov E.E., Skoch J., Hyman B.T., Klunk W.E., Bacskai B.J., Swager T.M. ( 2005 ) In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew Chem ; 44 : 5452 – 5456.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1747-0285.2007.00557.x.pdf
Size:
579.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.